Congo president says Ebola outbreak should be over this year

An outbreak of Ebola in eastern Democratic Republic of Congo should be eradicated by the end of 2019, Congolese President Felix Tshisekedi said on Friday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

[The New Humanitarian] GOMA, Democratic Republic of Congo -The Democratic Republic of Congo's deadliest ever Ebola outbreak has shown signs of slowing in recent weeks, but militia attacks, anti-UN protests, and chronic community distrust are undermining the 16-month effort to end the epidemic.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
Recent occurrences of filoviruses and the arenavirus Lassa virus (LASV) in overlapping endemic areas of Africa highlight the need for a prophylactic vaccine that would confer protection against all of these viruses that cause lethal hemorrhagic fever (HF). We developed a quadrivalent formulation of VesiculoVax that contains recombinant vesicular stomatitis virus (rVSV) vectors expressing filovirus glycoproteins and that also contains a rVSV vector expressing the glycoprotein of a lineage IV strain of LASV. Cynomolgus macaques were vaccinated twice with the quadrivalent formulation, followed by challenge 28 days after the b...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Two experimental drugs each reduced the risk of death from Ebola when tested in an outbreak in the Democratic Republic of Congo.
Source: NIH Research Matters from the National Institutes of Health (NIH) - Category: Consumer Health News Source Type: news
[New Times] Rwanda and the Democratic Republic of the Congo Sunday unveiled a massive vaccination campaign against Ebola Virus Disease (EVD) for their residents who live within the vicinity of a possible Ebola outbreak.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
Up to 200,000 Regimens of Janssen ’s Investigational Ebola Vaccine to be Supplied to Rwanda for Use in Border Region near Democratic Republic of the Congo (DRC)
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
Violence against health workers in the Democratic Republic of Congo is complicating the response to a massive measles outbreak and accelerating the spread of the disease, which has claimed twice as many lives than an ongoing Ebola epidemic.
Source: CBC | Health - Category: Consumer Health News Tags: News/Health Source Type: news
- A stockpile of 500,000 doses of Ebola vaccine for emergency use in outbreaks of the deadly fever is being established by the global vaccine alliance GAVI.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
[WHO] Kinshasa, 5 December 2019 - Around 2.2 million children are to be vaccinated against measles in North Kivu, the Democratic Republic of the Congo (DRC), where efforts are underway to curb the world's second-worst Ebola outbreak amid persistent insecurity.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
Nine new confirmed cases were reported from 27 November to 3 December in the ongoing Ebola virus disease (EVD) outbreak in North Kivu and Ituri provinces. The confirmed cases in this week were reported from Mandima (56%,n=5) and Mabalako (44%,n=4) Health Zones. In the past two weeks, violence, widespread civil unrest, and targeted attacks have severely disrupted the Ebola response and restricted access to affected communities in multiple locations. As a result, several key activities of the response experienced diminished performance, including the volume of reported and investigated alerts and the number of contacts regis...
Source: WHO Disease Outbreaks - Category: Infectious Diseases Tags: news Source Type: news
We report a candidate lead (compound #5: ((10R)-10-(4-hydroxyphenyl)-11,12,14,16-tetraazatetracyclo[7.7.0.02,7.011,15] hexadeca-1(16), 2(7),3,5,8,12,14-heptaen-8-ol)) with high drug-likeness score, promising lead-likeness behaviour and high median lethal dose. The candidate lead compound #5 engages in hydrogen bonding and hydrophobic interactions with VP40 active site residues. Thus, the lead compound #5 is recommended for further in vitro and in vivo validations for further consideration. PMID: 31787811 [PubMed]
Source: Bioinformation - Category: Bioinformatics Authors: Tags: Bioinformation Source Type: research
More News: Congo Health | Ebola | Health | Outbreaks